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Summary
Background: Primary perichondrial cells and chondrocytes have been used to repair articular cartilage defects in tissue engineering studies
involving various animal models. Transfection of these cells with a gene that induces chondrocytic phenotype may form an ideal method to
affect tissue engineering of articular cartilage.
Design: A protocol for high-efficiency transfection of primary perichondrial and cartilage cells was optimized. Plasmids carrying the marker
-galactosidase (-gal), PTHrP and TGF-1 genes driven by a strong mammalian promoter were transfected into primary perichondrial cells
and chondrocytes. A three-step method was used to achieve high efficiency of transfection: (1) permeabilization of primary cells using a mild
detergent, (2) association of plasmid DNAs with a polycationic (poly-l-lysine) core covalently linked to a receptor ligand (transferrin),
(3) introduction of cationic liposomes to form the quaternary complex. For in-vivo assessment, polylactic acid (PLA) scaffolds seeded with
-gal transfected perichondrial cells were implanted into experimentally created osteochondral defects in rabbit knees for 1 week.
Results: The efficiency of transfection was determined to be over 70% in vitro. The transformed cells continued to express -gal, in vivo for
the entire test period of 7 days. Furthermore, primary perichondrial cells transfected with TGF-1 and PTHrP over-expressed their cognate
gene products.
Conclusion: The ability to transfect autologous primary perichondrial cells and chondrocytes with high efficiency using a non-viral system
may form a first step towards tissue engineering with these transformed cells to repair articular cartilage defects. © 2001 OsteoArthritis
Research Society International
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To date, ex-vivo gene therapy in articular cartilage repair
has remained a challenge, primarily due to the difficulty
of achieving high-efficiency gene transfer into primary
autologous cells derived from perichondrium or cartilage
tissues with non-viral techniques. Although viral vectors
have shown efficacy in transforming primary cells with high
efficiency1–7 and are useful gene therapy tools in life-
threatening situations, the use of non-viral methods for
gene delivery in non life-threatening situations, such as to
repair articular cartilage defects, remains a desirable goal8.
For instance, adenovirus vectors may induce host immune
response9–15 in some cases, while retroviral vectors
require dividing cells for integration15. In addition, there is a
minor chance that viral vectors may randomly integrate
into the host genome, posing risk of neoplastic248transformation15–17. Therefore, the quest for a high-
efficiency gene delivery system for primary autologous cells
that would preclude the possibility of an immune response
(i.e. non-viral) in non life-threatening conditions such as
articular cartilage defects has continued with the use of
either liposomes or ligand-polycations (e.g. transferrin-
poly-l-lysine). Using cationic liposomes gene transfection of
mammalian cells was achieved18,19 with efficiencies rang-
ing from 1% to 15%20–23. The non-viral transfection of
primary cartilage cells has been previously attempted, but
yielded low efficiencies24–26. Use of liposomes did not
result in any toxicity in vivo27. Another method involved the
use of transferrin-poly-l-lysine ligand-polycation complex
mediated transfection and yielded 7–8% transfection
efficiency28–30. Increased transfection efficiency was fur-
ther achieved by the inclusion of poly-l-lysine polycations to
the liposome transfection system31,32, while utilizing trans-
ferrin and cationic liposomes high-efficiency transfection of
a cultured cell line (NIH-3T3 cells) has been reported33.
However, to date none of these techniques has been
shown to be successful in attaining very high efficiency
(>70%) transfection of primary mammalian cells. The
development of a technique for the transfection of primary
cells is important because only these cells (as autologous
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LIPOSOMES
Cationic liposomes were prepared as follows: equimolar
amounts (63 M) L--phosphatidyl-ethanolamine and
dimethyldioctadecyl-ammonium bromide were mixed in
chloroform, dried as a film and resuspended in 1 ml deion-ized water. The aqueous solution was sonicated until the
desired (50–100 m) particle size was achieved—observed
as compact particles with size slightly smaller than the
nucleolus of mammalian cells displayed in a flattened
morphology in a culture plate under 900× magnification in
a light microscope.COVALENT BONDING OF LIGAND (TRANSFERRIN) WITH
POLY-L-LYSINE
Apo-transferrin was covalently linked to a positively
charged polymeric scaffold [poly-l-lysine (70 kDa)] using
standard biochemistry protocols that have been previously
published29.ISOLATION OF TISSUES (PERICHONDRIUM AND CARTILAGE)
Perichondrium from the rabbit ribs was extracted as
follows: the New Zealand white (NZW) rabbits (mature
8–10 months old, with closed epiphysis) were sacrificed
according to the animal subjects protocols at University of
California, San Diego (UCSD), and costal ribs were
removed using sterile procedures. Adhering tissue was
cleaned away from the ribs with the use of sterile surgical
instruments and perichondrium was isolated by breaking
the rib and peeling off the perichondrium tissue. Cartilage
was extracted as follows: mature NZW rabbits were
sacrificed36–38 as per the UCSD animal subjects’ protocol.
The knee joint cavity was opened using sterile techniques
and the full depth of cartilage tissue was carefully peeled,
using a surgical knife, from the femoral condyles and tibial
plateaus. The isolated tissues were washed three times in
antibiotic containing buffered salt solution (HEPES buffered
saline with penicillin/streptomycin (1500 U/ml)).CELL PREPARATION AND CULTURE SYSTEM (PERICHONDRIAL
CELLS)
The perichondrium tissue was incubated overnight at
37°C under sterile conditions in 0.1% collagenase (CLS-2,
Worthington Biochemical, Freehold, NJ) in -MEM
(-modified Earl’s medium, GIBCO BRL, Grand Island, NY)
containing 0.5 mM L-glutamate and 500 U/ml penicillin/
streptomycin supplemented with 10% fetal bovine serum
(FBS; Cansera Intern., Rexcale, Ontario, Canada). Cells
and tissue debris were isolated away from the media by
passage through a sterile 0.45-m filter. The cells and
tissue debris were enzymatically digested with 0.1%
hyaluronidase (Sigma, St Louis, MO) and trypsin (Irvine
Scientific, Santa Ana, CA) for 1 h. All cell cultures were
performed at 37°C with 5.0% CO2. Utilizing this protocol we
obtained 1×106 cells from 100 mg wet weight of tissue in
less than 48 h.CELL PREPARATION AND CULTURE SYSTEM (CHONDROCYTES)
Primary chondrocytes were isolated by enzymatic diges-
tion of the cartilage tissue as described previously52.
Briefly, chondrocytes were released by digestion, by 2 h of
incubation with 0.2% pronase (CalBiochem Inc., San
Diego, CA) and a subsequent 22 h of incubation with
0.025% bacterial collagenase P (Boehringer Mannheim,
Indianapolis, IN) at 37°C under 5.0% CO2. They were then
grown in Dulbecco’s modified Eagle’s medium/Ham’s F12carriers) could be used to repair34–37 articular cartilage
defects.
Our laboratory has used a protocol for articular defect
repair in the rabbit model where cells derived from the
costal perichondrium are seeded into a biodegradable
polylactic acid scaffold and implanted into an experimen-
tally created full thickness articular cartilage defect in the
rabbit femoral condyle. However, the success of this repair
is affected by the phenotype of the implanted cells36,37. We
have shown that the chondrocytic phenotype of cultured
perichondrial cells can be enhanced by exogenous TGF-
138. We initiated the present study based upon the
premise that cells transfected with an expression vector
carrying the TGF-1 gene would form the most efficient
vehicle for the localized delivery of this morphogen into the
repair site. In this study we describe a novel method to
achieve high-efficiency gene delivery into primary peri-
chondrial cells and chondrocytes. Using this system we
delivered a marker gene into primary perichondrial cells
and chondrocytes and show that transfection efficiency
greater than 70% can be achieved. When these cells were
implanted into an experimentally created osteochondral
defect in rabbit femoral condyle, the cells continued to
express the transfected gene throughout the test period of
1 week.
A TGF-1 expression vector carrying the TGF-1
gene downstream of the hCMV promoter/enhancer was
transfected into primary perichondrial cells from rabbit ribs
and showed increased TGF-1 specific gene expression.
Furthermore, we have initiated studies to determine the
functional effects of parathyroid hormone related protein
(PTHrP) and its truncated isomers in primary chondrocytes.
PTHrP is involved in the regulation of extracellular matrix
components and mineral deposition by chondrocytes.
PTHrP and parathyroid hormone (PTH) are similar in their
biological actions and are recognized by a common PTH/
PTHrP receptor. PTHrP has been reported to be localized
in fetal cartilage39, growing rat condylar cartilage40, and
fetal mouse’s Meckel’s cartilage41. PTHrP mRNA was also
expressed in chondrocytes located in proliferation zone of
tibial growth plate42, in articular chondrocytes and in peri-
articular perichondrium43,44. The PTHrP receptor was
expressed by mature chondrocytes expressing type II col-
lagen but not by hypertrophic chondrocytes expressing the
type X collagen45,46. A mouse strain deficient in PTHrP
showed diminution of chondrocyte proliferation, premature
maturation of chondrocytes and accelerated bone for-
mation47,48. PTHrP expression lies downstream of a devel-
opmentally regulated morphoregulator, Indian hedgehog
(Ihh)44 and TGF-149, and upstream of an apoptosis
related protein, Bcl-250. In order to initiate studies on
PTHrP mediated effects on chondrocytes, PTHrP (1-87
N-terminal truncated protein and 1-173 wild type isoform)51
constructs driven by the hCMV promoter/enhancer were
transfected into primary chondrocytes using the three-step
DTPLL method described here. The PTHrP expression in
these transfected cells was determined.
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FBS and 25 g ascorbic acid, 50 g Gentamicin/ml media.
After filtration through a nylon mesh 70 m cell strainer
(Falcon, Becton Dickinson Labware, Franklin Lakes, NJ),
the cells were resuspended at a density of 4×104 cells per
milliliter of total media into 10-cm diameter dishes or into
35 mm six-well plates or cell culture slides (Costar, Corning
Inc., Corning, NY), and incubated at 37°C under an atmos-
phere of 5.0% CO2. The medium was changed every
2 days. Only primary cultures (of 5–7 days duration) were
used in the transfection experiments.AMPLIFICATION AND PURIFICATION OF PLASMIDS CONTAINING THE
-GALACTOSIDASE, TGF-1 OR PTHRP GENES DRIVEN BY HCMV
PROMOTER/ENHANCER SEQUENCES
An expression vector for the -galactosidase gene
driven by the hCMV promoter/enhancer was obtained from
Promega Inc. (Madison, WI). The TGF-1 gene (ATCC)
and the PTHrP 1-87 and 1-173 constructs51 were inserted
downstream of an hCMV promoter/enhancer in mammalian
expression vectors. All plasmids were amplified and
purified using standard biochemistry technique53. Briefly,
E. coli (XL1-blue: Stratagene, Inc., La Jolla, CA) were
transformed with the plasmids. The transformed cells were
amplified, the plasmid was isolated by CsCl density
centrifugation and purified by passage through an A-5M
Biogel column (Biorad Inc, San Francisco, CA) as per
manufacturer’s protocols. Approximately 5 g of the puri-
fied plasmid was electrophoresed through a 1% agarose
gel and determined to be free of contaminating RNA or
chromosomal DNAs.TRANSFECTION TO TEST THE EFFICIENCY OF THE
DNA/TRANSFERRIN-POLY-L-LYSINE/LIPOSOME (DTPLL) COMPLEXES
Primary perichondrial cells from rabbit ribs were cultured
on tissue culture plates in media (-MEM containing
0.5 mM L-glutamate and 500 U/ml penicillin/streptomycin
and supplemented with 10% FBS), while primary chondro-
cytes were cultured in media consisting of DMEM/F12,
50/50, supplemented with 10% FBS and 25 g ascorbic
acid, 50 g gentamicin/ml media at 37°C under an atmos-
phere of 5.0% CO2. The cells were allowed to proliferate
and achieve 70–80% confluence on the 35-mm diameter
culture plate or culture slides (Costar, Corning Inc.) (i.e.
0.5×106 cells per plate). These cells were permeabilized
with 0.00175% (w/v) lysolecithin (Sigma, St Louis, MO) for
exactly 2 min. The cells were subsequently washed with
3 ml of serum free medium (SF--MEM). The DTPLL
technique has been summarized in Fig. 1. The purified
plasmid DNA (D) (4 g) was incubated with 16 l of 10 g/
l stock transferrin-poly-l-lysine complex (TPL) suspended
in 0.5 ml SF--MEM. Cationic liposome solution (24 l) was
diluted in 0.5 ml SF--MEM. The plasmid DNA/transferrin-
poly-l-lysine complexes (DTPL) were added to the lipo-
somes at a 1:1 ratio and allowed to form tertiary complexes
for 15–20 min at room temperature. The DNA/transferrin-
poly-l-lysine/liposome (DTPLL) tertiary complexes were
incubated for 5 h at 37°C in serum-free medium (-MEM)
with the previously permeabilized perichondrium and carti-
lage derived cells under an atmosphere of 5.0% CO2(Protocol summarized in Fig. 1). The media was replaced
with fresh media (-MEM containing 0.5 mM L-glutamateand 500 U/ml penicillin/streptomycin and supplemented
with 10% FBS).DETERMINATION OF TRANSFECTION EFFICIENCY IN VITRO
The -galactosidase gene was expressed for 48 h
and tested for gene expression by -galactosidase assay
with 5-bromo-4-chloro-3-indoyl--D-galactoside (X-gal) or
o-nitrophenyl--D-galactopyranoside (ONPG) (Promega)
reaction. For ONPG assay, equal amounts of the cell
extract was added to the 96-well plates and incubated
with 100 l of the assay buffer as per the recommendations
of the manufacturer and the absorbance was measured
at 420 nm in a microplate spectrophotometer. For
-galactosidase analysis, the cells were fixed in buffer
containing 0.25% v/v gluteraldehyde in 1× PBS. The fixed
cells were stained with X-gal solution [0.2% X-gal (from 2%
stock in DMF), 2 mM MgCl2, 5 mM K4Fe (CN)6, 3H2O and
5 mM K3Fe (CN)6 prepared in 1× PBS]. Transfected cells
expressing the active -gal enzyme turn blue. The staining
step was performed at 37°C for up to 8 h. Efficiency of gene
transfection in X-gal stained cells was determined as fol-
lows: five fields from each plate were viewed under the
microscope. The portion of blue cells was determined as a
% of total cells. The assessment was repeated for at least
three plates. Permeabilized and unpermeabilized primary
cells in 35 mm diameter tissue culture plates were trans-
fected using the following reagents: (1) liposomes (24 l)/
DNA (4 g), (2) transferrin and liposomes/DNA, (3)
transferrin, poly-l-lysine (Mw=70 kDa) and liposome/DNA,
(4) transferrin, poly-l-lysine (Mw=150 kDa) and liposome/
DNA, and (5) poly-l-lysine covalently linked to transferrin
(1:1 molar ratio) and liposome/DNA (the DTPLL complex).DETERMINATION OF TRANSFECTION EFFICIENCY IN VIVO
For cell implantation studies, the -gal gene was allowed
to express for 12 h in culture and the cells were seeded
into PLA scaffold according to the protocol described
previously36,37. Standard surgical and animal care pro-
cedures, published previously, were used to create a 3 mm
deep×3.7 mm diameter wide full thickness articular carti-
lage defect in three rabbits’ femoral condyles36,37. The
transfected cell-seeded PLA scaffold was press fitted into
the defect. The knee was sutured and the rabbits were
cared for using standard protocols. The femoral condyles
were harvested after 1 week and the -galactosidase
activity was tested using X-gal reagent. Harvested con-
dyles were dipped in 0.2% X-gal solution (shown above)
overnight, decalcified in EDTA, fixed in Bouin’s solution,
embedded in paraffin and sectioned into 5 m sections by
cutting along the midsagittal plane. Five central sections
per animal were analysed.ISOLATION OF DNA-FREE RNA AND RT-PCR TO STUDY TGF-1
GENE EXPRESSION
Total cellular RNA was purified from cells transfected
with TGF-1 containing vector or with the same vector
lacking the TGF sequences (i.e. mock transfection). The
cells were extracted with 4 M-guanidine thiocyanate/
phenol (water saturated) as previously described21. To
eliminate any possible carry-over genomic DNA contami-
nation, the RNA was digested with RNase-free DNase I
(RQ1-DNase I, Promega, Inc.) and extracted twice with
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precipitated in 70% v/v ice-cold ethanol. The RT-PCR was
performed using TGF-1 specific primers (5′-CTGGAC
ACCAACTATTGCTTC-3′ 5′-CTTGCGGCCCACGTAGTA
CAC-3′) and assessed as described previously38. As a
control, RT-PCR was performed on -actin gene. The PCR
amplification was performed for 30 cycles as the mid-point
of linear amplification, which was determined as follows:
PCR was performed from 20 to 34 cycles. The PCR
products for every other cycle (i.e. 22, 24, 26 etc.) were
electrophoresed on an agarose gel and the band intensity
was quantitated by image analysis of the gel scans using
the NIH image analysis software (NIH image v1.6). The plot
of image intensity vs cycle number was used to identify a
mid-point of linear amplification.PTHrP IMMUNOASSAYS
Twenty-four hours post-transfection the culture media
was replaced with culture media containing 1% FBS (i.e.
-MEM with 1× antibiotic solution, L-glutamate and 1%
FBS). PTHrP expression was studied in either conditioned
media or cell extracts. Cells were pelleted and resus-
pended in extraction buffer (0.25 M Tris pH 7.5, 0.25%Tween-20 (supplemented with 0.1% of Triton X-100)
and 0.25 mM EDTA) at a concentration of 106 cells/ml
extraction buffer. The immunoassay was performed using
rabbit antiserum to PTHrP 1-34 peptide as described
previously51.ResultsFig. 1. Schematic description of the three-step protocol for high-efficiency transfection of primary cells. A three-step method is described.
Where: D=plasmid DNA, T=transferrin, PL=poly-l-lysine, L=liposomes, DTPLL=DNA/transferrin/poly-L-lysine/liposomes complex.REAGENT OPTIMIZATION IN VITRO
In a series of experiments using different combinations of
liposomes, transferrin, transferrin-poly-l-lisine conjugates
and plasmids, the transfection efficiency of primary peri-
chondrial cells and chondrocytes was optimized. Various
combinations of the permeabilizing agents were also
attempted. The useable range of permeabilization reagent
was defined as the concentration at which minimal cell
death occurred (approx. <1%) following 24 h of culture.
Inclusion of transferrin in the transfection of the permeabil-
ized cells gave efficiency of about 25%, whereas inclusion
of poly-l-lysine (Mw=70 kDa) alone produced transfection
efficiency of 20%. Use of unbound transferrin and poly-l-
lysine (70 kDa) resulted in efficiencies as high as 40%. The
use of poly-l-lysine of Mw 150 kDa (at the concentrations
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use of DNA/Transferrin-poly-l-lysine (covanlently bonded)
and cationic liposomes (DTPLL) together resulted in
greater than 70% transfection efficiency (data summarized
in Table I).TRANSFECTION EFFICIENCY USING OPTIMIZED CONDITIONS
IN VITRO
The transformation efficiency was determined by test for
-galactosidase enzyme activity by the X-gal reagent. Blue
cells were indicative of -galactosidase activity (Fig. 2).
Transfection of primary rabbit perichondrial cells and
chondrocytes using this method gave efficiencies of over
70% [Fig. 3(b)] as compared with the mock (plasmid
lacking the -galactosidase gene) transfection [Fig. 3(a)].
ONPG reaction (-gal converts ONPG to o-nitrophenol
(yellow) and galactose) was used to confirm the staining
assay and showed that the inclusion of transferrin-poly-l-
lysine (TPL) enhanced transfection efficiency into permea-
bilized cells significantly as measured by optical density at
420 nm (Fig. 4).TEST OF SYSTEM EFFICACY IN VIVO IN A RABBIT IMPLANTATION
MODEL
For in-vivo implantation transfected perichondrial cells
were seeded into a PLA scaffold 24 h post-transfection andplaced into a 3×3.7 mm defect in the rabbit femoral
condyles. The condyles were harvested 1 week post-
implantation and assessed qualitatively for -gal enzyme
activity. Cells in the surface layer of the implant were found
to be positive for -galactosidase gene activity harvested 1
week post-implantation (Fig. 5), implying that the seeded
cells continued to express the transfected gene.
Primary perichondrial cells transfected with TGF-1
expression vector showed increased mRNAs for TGF-1
by semi-quantitative RT-PCR (Fig. 6). Primary chondro-
cytes were transfected with PTHrP genes 1-87 and 1-173
expression constructs and resulted in increased PTHrP
gene expression (Fig. 7) measured using the anti-PTHrP
1-34 antibodies. The cartilage cells demonstrated both
secretion and storage of PTHrP in the non-transfected,
basal state and over expression of PTHrP 1-87 from the
CMV promoter-driven PTHrP 1-87 plasmid after transfec-
tion (approximately 10-fold above basal level in the media
and over two-fold in the cell extract). Transfection with
PTHrP 1-173 plasmid did not show over-expression of
PTHrP in the media [Fig. 7(a)] but did demonstrate a 50%
increase in the level of PTHrP in the cell extract. These
transfected cells continued to express PTHrP for at least 13
days post-transfection (data not shown). These results are
consistent with the observation that, elimination of the
carboxy-terminal sequences of PTHrP 1-173 (i.e. 1-87
construct) increased the production and secretion of the
truncated form51.Table I
Efficiency of gene transfection into permeabilized primary perichondrial cells
Treatment Efficiency (%)
DNA+Transferrin+Liposomes 26.3±4.0
DNA+Transferrin+Poly-l-lysine+Liposomes 40.8±8.7
DNA±covalently linked Transferrin-Poly-l-lysine+Liposomes 71.1±11.6
Efficiency of expression was determined microscopically by counting -galactosidase positive ‘blue’ cells.Fig. 2. Transfection of primary perichondrium derived cells by the
DTPLL method outlined in Fig. 1. An example of a microscopic field
of the X-gal-stained cells. Cells were transfected at 70–80%
confluence, allowed to grow to for 48 h, and assayed for enzyme
expression by X-gal. -Galactosidase expression monitored by in
situ X-gal staining (blue cells)—most cells in this field were labeled
blue.Fig. 3. A representative microscopic field showing high-efficiency
transfection of primary chondrocytes for -gal activity by in-situ
X-gal staining (blue cells). (A) Mock transfection with the CMV
plasmid lacking the -gal gene sequences. (B) Transfection with
the -gal plasmid as described in Methods. The foci are present
in normal confluent cultures of primary chondrocytes but are
visualized when cells are stained (B).Discussion
The efficacy of the protocol described here could
be attributed to the following sequence of events:
(1) permeabilization: the cell membrane was made slightly
porous prior to the introduction of genes into the cells with
the help of a mild detergent (lysolecithin), (2) ligand/
polycationic complex: a specific ligand (transferrin) was
Osteoarthritis and Cartilage Vol. 9 No. 3 253Fig. 4. Assessment of relative transfection efficiency by ONPG assay. Equal amounts of the cell extracts of transfected perichondrium (A)
transfected using liposomes alone or the DTPLL method and cartilage cells (B) either mock transfected or transfected with the marker (-gal
expression plasmid) were analysed by the ONPG assay described in Methods. Relative -gal activity was assessed for differences in optical
density (OD) at 420 nm.Fig. 5. In-vivo assessment of transfected primary perichondrial cells. Cell seeded PLA cores were seeded into experimentally created
osteochondral defects in the rabbit femoral condyles. Assessment of -gal enzymatic activity by X-gal 1 week post-implantation. (A) X-gal
and eosin stained sections. (B) Staining with the X-gal solution alone. (C) High resolution image of a representative X-gal stained section.Fig. 6. Analysis of TGF-1 in transfected primary perichondrial
cells by RT-PCR. RT-PCR products were electrophoresed on an
agarose gel and visualized by ethidium bromide intercalation.
Expected sized products (495 bps) were observed for the control
and TGF-1 (T) transfected cells. The -actin gene expression did
not vary between control (C) and TGF-1 transfected (T) cells.covalently attached to a polycationic core (poly-l-lysine) to
create a scaffold to facilitate ionic interaction with nega-
tively charged DNA, (3) ligand/receptor interaction: theDNA/ligand-poly-l-lysine-complex was delivered very close
to the cell due to the binding of the ligand to its receptor (i.e.
the receptor ligand interaction), and (4) cationic liposome
mediated delivery: the DNA is putatively delivered into the
cell by hydrophobic interactions between the cationic lipo-
somes20 and the cell membrane that had been previously
permeabilized.
This gene delivery protocol has shown efficacy in vitro
and in vivo in an animal model. In vitro, more than 70% of
primary perichondrial cells and chondrocytes were deter-
mined to be positive for the transfected gene by X-gal
staining (Figs 2 and 3) and relative reaction with ONPG
(Fig. 4). These cells were implanted in the rabbit knee
into an experimentally created osteochondral defect. After
1 week the defect contained cells that continued to
express the transfected gene. The staining was primarily
observed on the top portion (cartilage surface) of the
implanted cells (Fig. 5). This observation implies the
possibility that cells in the inner core of the implanted
scaffold are unable to express any active -gal enzyme,
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in this size scaffold following 1 week of in-vivo
implantation.
The expression of the 1-87 truncated PTHrP construct in
the media fraction was several fold larger than its wild-type
isomer 1-173 in transfected primary chondrocyte cultures,
while, expression in the cellular fraction was about two-fold
as large (Fig. 7). These relative differences are consistent
with the observation that elimination of the carboxy-
terminal sequences of PTHrP 1-173 increases production
and secretion of the truncated 1-87 isomer51. Primary
perichondrial and chondrocytic cells transfected with
TGF-1 and PTHrP form the first part of the studies to show
physiological growth and regulatory changes, such as
changes in cell proliferation and gene expression.
The DTPLL transfection system is envisioned to be
generally applicable for gene therapy using stem cells
from the perichondrium, periosteum or chondrocytes54.
Introduction of morphoregulatory factors such as TGF-
138,55–58, PTHrP43,44,47, connective tissue growth factor
(CTGF) and bone morphogenetic proteins (i.e. BMP-2)57,58
and transcription factors (e.g. SOX-9)59,60 may enhance
chondrogenic phenotype of these cells or may lead to the
development of more physiologically relevant cell culture
models for functional studies. In previous studies, primary
cultured perichondrium, bone marrow, periosteum and car-
tilage derived cells have been shown to partially enhance
repair of osteochondral defects in animal models34,36,37,54.
The duration of expression of the transfected gene has
been noted here for the entire study period of 1 week in the
animal model. The gene expression following this period
remains to be determined. The phenotypic changes
induced by the transfected cells in this time period may,
however, be sufficient to enhance cartilage repair. We
anticipate that in the near future spatially and temporally
restricted over-expression of morphoregulatory factors or
transcription factors in primary autologous cells and subse-
quent implantation of these in cell-seeded cores (such as
the PLA) may form a useful therapeutic modality for tissue
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reaction; CTGF, connective tissue growth factor.Fig. 7. PTHrP protein expression in transfected primary chondrocytes: PTHrP levels were assessed by immunoassays using anti-PTHrP
(1-34 peptide) antibody in (A) culture media and (B) cell extracts 3 days post-transfection.References
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